Flufeme

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flufeme

Property Description
Active ingredient Fluconazole
Form Tablet, Capsule, Oral Suspension, Intravenous Solution
Pharmacological class Systemic Antifungal Agent; Azole Antifungal
Common use Treatment of internal fungal infections (mycoses)
Origin Synthetic triazole derivative

What Type of Medicine is Flufeme and What is its Purpose?

Flufeme is defined as a systemic antifungal agent containing the active compound Fluconazole, classifying it as a triazole antifungal within the broader azole group. This medication is restricted to a prescription-only status, reflecting its potency and systemic action. The overall purpose of Flufeme is to manage and control mycoses, infections caused by fungi that are often deep-seated or widely distributed in the body.

Fluconazole is included on the Model List of Essential Medicines, as it is a foundational tool for treating serious fungal overgrowth. The triazole structure of Fluconazole is characterized by its action against fungal pathogens, and is used for internal infections.


Composition and Forms: Is Flufeme a Synthetic Triazole Derivative?

The medication is a single active ingredient product, deriving its therapeutic effect entirely from Fluconazole, which is a compound developed synthetically rather than found naturally. This synthetic triazole antifungal agent is designed for absorption and distribution throughout the body.

Flufeme is available in multiple pharmaceutical preparations to ensure systemic delivery. This includes oral forms, such as the capsule and tablet, as well as a sterile solution for intravenous infusion. The availability of both oral and intravenous administration routes is a distinctive feature, ensuring consistency of the active substance's concentration regardless of whether the treatment is administered via intravenous therapy or oral treatment.

Regulatory References

  1. WHO Essential Medicines List
  2. Fluconazole - StatPearls - NCBI Bookshelf

What side effects are possible with Flufeme?

The safety profile of Flufeme (Fluconazole) is documented in official regulatory sources, with adverse reactions grouped by the affected physiological system and frequency of occurrence.

Adverse Reaction Classifications

Classification Representative Effects (System-Organ Class)
Very Common (ge 10%) Headache (Nervous System)
Common (1% to <10%) Nausea, Abdominal Pain, Vomiting, Diarrhoea (Gastrointestinal); Rash (Skin); Increased Liver Enzymes (Hepatobiliary)
Rare (<0.1%) Torsade de Pointes (Cardiac); Hepatic Failure (Hepatobiliary); Agranulocytosis (Blood); Anaphylaxis (Immune)

Serious Adverse Reactions and Safety Constraints

Official labeling explicitly documents the risk of severe, rare reactions. These include potentially fatal hepatic toxicity and serious cutaneous reactions like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The reaction Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has also been reported in post-marketing surveillance.

Flufeme is contraindicated in patients with a known hypersensitivity to the drug or other azole antifungals. Due to the potential for QT interval prolongation, co-administration with other specific medications known to prolong the QT interval (e.g., cisapride, quinidine) is restricted in regulatory documents.

Population-Specific Safety Notes

Regulatory information notes that the disposition of Fluconazole is markedly affected by a reduction in renal function. This consideration is particularly relevant for geriatric patients, whose altered safety profile is often associated with age-related kidney function changes. The risk of serious hepatic toxicity is primarily observed in patients with serious underlying medical conditions.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes specific central nervous system symptoms that have been reported in cases of overdose involving the active ingredient in Flufeme. The most commonly documented overdose presentations relate to mental and psychological changes.

Overdose may be associated with the following acute clinical manifestations:

  • Hallucination: Seeing, hearing, or feeling things that are not actually present.
  • Paranoid Behavior: Manifesting as suspiciousness, fearfulness, or other extreme changes in mental state.

If the use of excessive amounts of Flufeme is suspected, urgent medical attention is required, as stated in authorized prescribing information. This includes cases where there are no immediate signs of discomfort or poisoning.


Overdose Management Statements
Immediate Action Required: Contact a Poison Control Center or immediately go to the Emergency Department at the nearest hospital.
Symptomatic Treatment: In the event of an overdose, medical professionals should institute symptomatic treatment, along with general supportive measures.
Excretion: Because the active ingredient is largely excreted in the urine, a three-hour hemodialysis session is known to decrease its plasma concentration by approximately 50%.

These statements define the critical steps for managing intoxication. The documented symptoms of overdose are primarily psychiatric in nature, emphasizing the need for immediate professional medical evaluation and management of supportive care.

Therapeutic Uses of Flufeme

What Flufeme Treats: Main Uses and Benefits

Flufeme (Fluconazole) is commonly used for managing active fungal infections and provides supportive symptomatic relief across a wide spectrum of fungal infections (mycoses). This medication is applicable in treating systemic or invasive candidiasis, and is also used for localized infections like Cryptococcal Meningitis, oral and esophageal candidiasis, and various recurrent dermal and genital fungal conditions (e.g., vaginal candidiasis, tinea infections). Generally, this supports easing the overall symptom load.

It is used in clinical settings that involve acute or unstable symptom patterns, such as managing the pronounced systemic symptoms associated with candidemia or the neurological symptoms linked to organ-specific functional stress. The benefit contributes to comfort and assists with maintaining functional stability, particularly when symptoms become more noticeable.

“Flufeme is commonly used across conditions presenting with acute episodes, providing supportive relief when symptoms interfere with routine activities.”


Quick Fact: Relief for Soreness and Itching

Flufeme is relevant for easing symptoms related to inflammatory or irritative states in the mucous membranes and skin, supporting patients during episodes of heightened discomfort.

Regulatory References

  1. NIH MedlinePlus overview on Fluconazole

Eligibility and Restrictions for Use

The eligibility for Flufeme (Fluconazole) is strictly governed by regulatory documentation, which defines absolute prohibitions and conditions for restricted use.

Absolute Contraindications

Flufeme is prohibited for patients with known hypersensitivity to Fluconazole or other azole compounds. It must not be used concurrently with certain medications that prolong the QT interval and are metabolized by the CYP3A4 enzyme (e.g., cisapride, astemizole). Oral forms are also contraindicated in individuals with rare hereditary sugar metabolism disorders (e.g., Lapp lactase deficiency).

Conditional Use and Restrictions

Population/Condition Restriction Status
Impaired Renal Function Dose reduction is required, as the medicine is primarily cleared by the kidneys.
Liver Dysfunction Use requires caution due to the potential for rare hepatotoxicity.
Newborns & Infants Permitted for serious infections, but dosing intervals must be adjusted.
Pregnancy Not recommended for standard therapy; reserved for life-threatening infections.
Breastfeeding Permitted after a single 150 mg dose; not recommended after repeated or high-dose use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Flufeme (Fluconazole) is defined primarily by its role as an inhibitor of drug-metabolizing enzymes, which affects the systemic exposure of co-administered medicines, as documented in official regulatory sources.


Documented Pharmacokinetic Interactions

Flufeme is documented as a potent inhibitor of the hepatic enzymes CYP2C9 and CYP2C19, and a moderate inhibitor of CYP3A4. This mechanism governs the official interaction profile and leads to changes in plasma concentrations for numerous medicinal products, classified into the following official categories:

  • Formally Contraindicated Combinations: Co-administration is prohibited with several QT-prolonging agents that are metabolized via the CYP3A4 pathway, including Cisapride, Pimozide, Quinidine, and Erythromycin. The co-administration of Terfenadine is also restricted at Flufeme doses of 400 mg/day or higher.
  • Increased Exposure of Co-administered Drugs: Flufeme is documented to increase the exposure (AUC/Cmax) of substances like Warfarin, certain Statins (e.g., Atorvastatin, Simvastatin), Immunosuppressants (e.g., Cyclosporine, Tacrolimus), and Oral Contraceptives.
  • Decreased Flufeme Exposure: Certain anti-tuberculosis agents, such as Rifampicin, are documented to reduce the systemic exposure and half-life of Flufeme.

Other Constraints

The regulatory profile notes that Flufeme may be taken without regard to meals, as food does not clinically affect its absorption. Additionally, the drug's clearance is markedly reduced in individuals with impaired renal function, a factor that affects the resulting concentration of Flufeme when combined with certain diuretics.

Mechanism of Action

The mechanistic action of Flufeme, containing Fluconazole, is strictly defined by its selective intervention in the essential biology of fungal pathogens, leading to a fungistatic consequence: the inhibition of fungal growth and replication.


Molecular Targeting: Blocking Fungal Sterol Synthesis

This mechanism centers on the competitive inhibition of a vital fungal enzyme, lanosterol 14-alpha demethylase (CYP51). The drug binds to the enzyme's heme iron atom, halting the pathway that produces ergosterol, the key stabilizing sterol of the fungal cell membrane.


Cellular Cascade: Compromising Membrane Integrity

The failure to synthesize ergosterol forces the fungal cell to incorporate abnormal, bulky sterols, leading to a profound structural defect. This compromise increases the cell's permeability and fragility, resulting in the physiological consequence of arrested fungal cell proliferation.


Mechanistic Constraints and Selectivity

The mechanism exhibits high selectivity for the fungal CYP51 enzyme over human P450 enzymes. The mechanism's influence, however, is constrained by fungal countermeasures such as the overexpression of efflux pumps or mutations in the ERG11 gene, which reduce the drug's binding affinity and can permit the pathogen to resume ergosterol synthesis.

Dosage and Administration Information

How Flufeme is Used: Official Administration Guidelines

Flufeme (Fluconazole) is associated with specific administration parameters, which detail routes, dose regimens, and duration patterns. The daily dose for oral administration (capsules, tablets, suspension) is the same as the dose for intravenous (IV) infusion, as the medication is well-absorbed by the body.

Administration Element Official Labeled Instruction
Route of Administration Oral (capsule, tablet, suspension) or Intravenous (IV) solution (2 mg/mL).
Timing Relative to Meals May be taken with or without food.
Dosing Frequency Typically administered once daily for multiple-dose regimens.
Loading Dose For systemic infections, a dose twice the usual daily dose is given on Day 1 to achieve rapid steady-state concentrations.

For localized conditions, such as acute vaginal candidiasis, the dosage is often a single oral dose of 150 mg. For conditions requiring long-term management, such as relapse suppression for cryptococcal meningitis, treatment may be continued at a maintenance dose (e.g., 200 mg once daily).

Special Procedural Instructions

For the oral suspension, the powder is reconstituted and shaken well before use. When administering the IV infusion, the maximum rate of infusion does not exceed 10 mL per minute. Dosing is adjusted for pediatric patients based on body weight (mg/kg). Dose reduction is utilized for adults with impaired kidney function (creatinine clearance leq 50 mL/min) after the initial loading dose; dialysis patients receive 100% of the recommended dose after each dialysis session.

Recent Clinical Evidence

Research Evidence: Overview of Clinical Studies for Flufeme

Evidence for Systemic and Bloodstream Fungal Infections (Candidiasis)

The research landscape for Flufeme evaluated in serious internal infections, such as Candidemia, includes Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies explored how Flufeme compares to other antifungal medications or evaluated its use in different phases of patient care.

Researchers monitored endpoints like mycological eradication (fungal clearance) and overall survival in hospitalized adult populations. For example, some trials described patterns in both fungal clearance and survival rates in the populations studied.

Research is heterogeneous for certain groups, particularly patients with very low immune cell counts. Furthermore, evidence provides limited insight into outcomes for non-albicans Candida species that may show decreased susceptibility to this class of medication.


Evidence for Cryptococcal Meningitis and CNS Infections

Flufeme's role in managing Cryptococcal Meningitis (CM) has been extensively studied, particularly in adults with advanced HIV infection. Trials explored initial high-intensity study phases and extended phases exploring outcomes related to recurrence.

Outcomes primarily measured were the rate of fungal clearance from the Cerebrospinal Fluid (CSF) and the frequency of relapse or progression. Research monitored patients and observed that combining Flufeme with other antifungal medications was associated with monitored changes in CSF status compared to when it was used alone in the initial phase.

What remains uncertain is the full picture for patients who are not HIV-positive, as large-scale RCTs in this group are limited. Research is also complex due to multi-drug regimens, which can restrict the ability to determine the effects of Flufeme alone on certain outcomes.


Evidence for Preventing Invasive Fungal Infections (Prophylaxis)

Flufeme was studied for prophylaxis in specific groups considered to be at high risk, such as Very Low Birth Weight (VLBW) preterm neonates and adults receiving Hematopoietic Cell Transplants. Key outcomes monitored included the incidence of invasive candidiasis. Studies monitored patterns related to the incidence of invasive candidiasis in VLBW infants who were evaluated.

A significant point of uncertainty involves the potential for long-term emergence of antifungal resistance. The research provides context for outcomes in prophylaxis studies; however, the overall impact on all-cause mortality in VLBW infants remains a complex area with varying findings across studies.

Key Studies & References WHO Model List of Essential Medicines (Used for overall context, indications, and global relevance)

Frequently Asked Questions (FAQ)

Common questions about Flufeme (FAQ)

Q: How quickly does Flufeme start to work after I take it?

According to official product information, the highest concentration of Flufeme in the bloodstream typically occurs between 1 and 2 hours after an oral dose. For certain serious conditions, a higher dose (a 'loading dose') is detailed for the first day to establish blood concentrations that are closer to steady-state by the second day.

Q: Can I take Flufeme if I am also taking an over-the-counter pain reliever?

Regulatory documents list numerous drug-drug interactions, particularly with medicines that affect the body's drug-metabolizing enzymes (CYP enzymes). Regulatory documents do not formally list common over-the-counter pain relievers as prohibited combinations.

Q: Does Flufeme interact with vitamins or herbal supplements?

Official labeling focuses on documented drug-drug interactions with prescription medicines. While most vitamins and herbal supplements are not specifically listed as interacting, the liquid oral suspension form of Flufeme does contain sucrose (sugar). This is a consideration for individuals with specific hereditary sugar malabsorption issues.

Q: What is the longest period of time people typically stay on Flufeme?

For managing certain severe or chronic conditions, such as preventing the relapse of cryptococcal meningitis, official treatment recommendations indicate that the maintenance therapy may be continued indefinitely under clinical supervision. The specific duration depends on the condition being addressed.

Q: Are there any known issues with drinking alcohol while using Flufeme?

The official safety profile for Flufeme includes a documented risk of serious hepatic toxicity (liver damage). Clinical guidance associated with the medication suggests caution regarding the consumption of alcoholic drinks.

Q: Can Flufeme affect my sleep pattern?

Official listings of side effects include somnolence (drowsiness) as an uncommon adverse effect, meaning it is seen in approximately 0.1% to 1% of patients. The most common nervous system-related side effect reported is headache.

Q: What should I do if a side effect of Flufeme does not go away?

Official safety information notes that if signs of serious adverse reactions, such as severe rash or liver problems, develop, an assessment is warranted. The documentation provides factual information to help patients recognize these suggestive symptoms.

Q: Has Flufeme been studied in pregnant women?

Official reviews have reported on the use of Flufeme during pregnancy. They note that the use of high doses (400 to 1200 mg per day) for several weeks during the first trimester has been associated with a documented pattern of congenital abnormalities in the children of the mothers studied.

Q: Can Flufeme affect my ability to drive or operate machinery?

Official warnings note that the drug may occasionally cause side effects such as dizziness or seizures. Due to this possibility, regulatory documentation notes that caution is required when driving or operating machinery while using this medication.

Q: Does Flufeme have any known interactions with birth control pills?

Official product information documents that Flufeme can increase the systemic exposure (the amount in the body) of oral contraceptives. This is a documented pharmacokinetic interaction listed in regulatory labeling.

Q: Can I take Flufeme if I have kidney problems?

The drug's processing is significantly affected by reduced renal function (kidney function). Regulatory guidelines state that the dose may need to be reduced in adults with impaired kidney function after the initial dose.

Q: Can I take Flufeme if I have liver disease?

Official safety warnings indicate that the drug should be administered with caution to patients who have existing liver dysfunction. Patients who develop abnormal liver function tests while on the drug must be closely monitored for serious hepatic injury.

Q: Is it normal to feel tired when first starting Flufeme?

The official safety documentation lists fatigue (unusual tiredness or weakness) as an uncommon side effect, meaning it is reported in less than 1% of patients. It is a documented possibility.

Q: Does Flufeme cause hair loss?

Alopecia (hair loss) is a documented adverse effect of Flufeme. This effect is primarily associated with the use of higher doses (400 mg per day or greater) over a long period. This change is noted in regulatory literature as typically resolving upon discontinuation or dose reduction.

Q: Is there a generic version of Flufeme available?

Yes. According to official sources and regulatory information, the drug is available as both a generic drug (Fluconazole) and under various brand names.

Q: Can older adults use Flufeme safely?

Official documents note that the drug’s half-life and concentration are generally higher in older adults. This requires dose consideration based on age-related changes in kidney function, which affect how the drug is cleared from the body.

Q: Why is Flufeme prescribed for multiple different health issues?

Flufeme is classified as a triazole antifungal and possesses a broad spectrum of activity against various types of fungal pathogens. This wide range of documented activity allows it to be used to address multiple different infections that are caused by these susceptible organisms.

Q: Is it necessary to take Flufeme with food?

No. Official regulatory documents state that the drug's absorption is unaffected by food intake. Therefore, it may be taken with or without food.

Q: Is Flufeme approved for use in children?

Yes. Official regulatory documents contain specific dosing protocols and detailed pharmacokinetic data for the use of Flufeme in pediatric patients, including newborns.

Q: Are there different strengths of Flufeme tablets?

Yes. Official dosage guides list multiple available strengths for the oral capsules and tablets. These typically include strengths such as 50 mg, 100 mg, 150 mg, and 200 mg.

Q: What is the chance of experiencing a rare side effect from Flufeme?

Official regulatory sources classify adverse reactions based on how often they occur. A side effect classified as rare means it is officially reported as occurring in less than 0.1% of patients in clinical trials and post-marketing surveillance.

Q: Is Flufeme ever prescribed in combination with other drugs for the same condition?

Yes. Clinical research has studied the use of Flufeme in combination with other antifungal medications, particularly in the initial, high-intensity treatment phases for certain serious conditions like cryptococcal meningitis.

Q: Can Flufeme affect my mood or emotional state?

Regulatory safety documents note that mood changes have been reported in post-marketing surveillance. Furthermore, symptoms like fearfulness, suspiciousness, or other mental changes are documented in cases of overdose.

Q: How does the body eliminate Flufeme?

Flufeme is primarily eliminated from the body by renal excretion, meaning it is cleared through the kidneys and removed in the urine. Approximately 80% of the administered dose is eliminated in the urine as the unchanged drug.

Q: What kind of studies led to the approval of Flufeme?

The approval of Flufeme was supported by clinical evidence, including Randomized Controlled Trials (RCTs) and systematic reviews. These studies explored the drug's effectiveness, pharmacokinetics (how the body handles the drug), and safety in populations with fungal infections.

Q: Why do I need a prescription for Flufeme?

Flufeme is classified as a prescription-only antifungal because it is used to manage serious, life-threatening fungal infections. Regulatory bodies require that its use be supervised for safety monitoring, appropriate dosing, and management of potential interactions.

Q: How is Flufeme different from similar drugs mentioned in the 'How it works' section?

Clinical literature notes that Flufeme is unique among similar azole antifungals for being eliminated primarily via the kidney. Other drugs in this class are mainly eliminated through the liver.

Q: Does Flufeme expire?

Yes. Official labeling mandates specific stability rules, particularly for the liquid forms. The powder for the oral suspension, for instance, must be discarded after 14 days of mixing, and all forms must be stored within a specific temperature range to ensure drug stability.

How should Flufeme be stored and disposed of?

How to Store and Dispose of Flufeme (Fluconazole)

The official labeling mandates specific conditions for storing Flufeme to ensure its stability. The product must be kept at room temperature, typically below 30 C, and protected from excessive heat, moisture, and direct sunlight. Flufeme must remain in its original container and be kept tightly closed.

Child Safety and Stability

All forms of this medication must be stored out of the sight and reach of young children. For the liquid oral suspension, any unused portion must be discarded after 14 days of mixing, and the suspension should not be frozen.

Disposal Requirements

Do not dispose of unused or expired Flufeme by flushing it down the toilet or pouring it into a drain. Instead, regulatory guidelines require that unwanted medication be taken to a pharmacy or official drug take-back program for safe and environmentally responsible disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flufeme found in:

A-Z Index: